MedTrace Logo

Olmesartan Medoxomil Versus Losartan Potassium in Patients With Mild to Moderate Essential Hypertension

NCT00856271 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 287

Last updated 2010-09-29

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of olmesartan medoxomil compared with losartan potassium in patients with mild to moderate essential hypertension.

Conditions

  • Essential Hypertension

Interventions

DRUG

olmesartan medoxomil

oral tablets, once daily for 8 weeks

DRUG

losartan potassium

capsules, once daily for 8 weeks

Sponsors & Collaborators

  • Shanghai Sankyo Pharmaceuticals Co., Ltd.

    collaborator UNKNOWN

  • Daiichi Sankyo

    lead INDUSTRY

Principal Investigators

  • Vice President · Sankyo Shanghai Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-08-31
Primary Completion
2005-02-28
Completion
2005-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00856271 on ClinicalTrials.gov